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Summary The c-myc oncogene has been extensively implicated in cell proliferation, cell differentiation and
programmed cell death. Aberrant expression of the c-myc gene product has been observed in a range of
tumours and has also been implicated in cisplatin (cis-dichlorodiammineplatinum)-mediated chemoresistance. A
solid transplantable tumour model in syngeneic DA rats was subjected to treatment with cisplatin to determine
the impact of such therapy on endogenous c-myc gene expression. Serially transplanted tumours were
intravenously treated with a single cisplatin dose (1 mg kg-1) and c-myc expression analysed 2 and 7 days after
treatment. The surviving tumour cells display a significant 2-fold elevation in c-myc expression at 48 h and 7
days after treatment. Primary cell cultures have been derived from untreated in vivo tumours of the same model
and subjected to treatment with a c-myc phosphorothioate antisense oligomer. Administration of 5 gM c-myc
antisense oligomer directed at the initiation codon and first four codons of c-myc mRNA results in total
inhibition of c-myc expression and coincident suspension of cell growth for a period of 4 days in culture.
Antisense therapies directed at the c-myc gene may well prove an effective tool for treating tumours in
conjunction with cisplatin as these findings show that tumour cells surviving cisplatin chemotherapy display
elevated c-myc expression.
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The c-myc proto-oncogene, an evolutionary conserved gene
found in all vertebrates, is implicated in the regulation of cell
proliferation, mitogenesis, differentiation and programmed
cell death (Spencer and Groudine, 1991). Expression of c-myc
is induced in proliferating cells following mitogenic stimula-
tion (Kato et al., 1992) but is down regulated in quiescent
cells following factor withdrawal (Lotem and Sachs, 1993;
Hermeking and Eick, 1994). Activation of c-myc has been
associated with tumours of the breast (Watson et al., 1993),
colon (Smith et al., 1993), ovary (Tashiro et al., 1992) and
squamous cell carcinomas (Ogunbiyi et al., 1993). Signifi-
cantly, c-myc gene activation has been correlated with poor
clinical prognosis for aggressive tumours including bladder
cancer (Kotake et al., 1990) and human non-small-cell lung
carcinoma (Volm et al., 1993).
Several in vitro studies of tumour cell lines suggest that
elevated c-myc expression can confer resistance to cisplatin
(Sklar and Prochownik, 1991; Niimi et al., 1991; Mituzani et
al., 1994). Cisplatin (cis-diamminedichloroplatinum; CDDP)
is an antineoplastic agent with demonstrated clinical
effectiveness against hormone-resistant prostate cancer
(Yagoda and Petrylak, 1993), ovarian carcinoma (Mark-
man, 1993) and as a radiation sensitiser for advanced solid
head and neck tumours (Chougule et al., 1994; Nakata et al.,
1994).
Resistance to cisplatin and other chemotherapeutic agents
represents a major obstacle to effective cancer therapy as
clinically significant levels of resistance emerge rapidly
following treatment (Andrews and Howell, 1990; Kashani-
Sabet et al., 1990). Chemoresistance to cisplatin is typically
generated by exposure of tumour cells in vitro to gradually
increasing concentrations of the drug (Twentyman et al.,
1991; Christen et al., 1993) or fractionated X-irradiation
(Eichholtz-Wirth et al., 1993; Taverna et al., 1994). Reported
mechanisms for acquired cisplatin resistance include increased
mRNA and enzyme activity of dTMP synthase (Scanlon and
Kashani-Sabet, 1988), induction of DNA repair enzymes
(Scanlon and Kashani-Sabet, 1989; Kelland et al., 1992),
decreased drug accumulation (Gately and Howell, 1993),
increased levels of glutathione (Godwin et al., 1992), hsp60
chaperonins (Nakata et al., 1994) and metallothioneins
(Kasahara et al., 1991). Cisplatin chemoresistance is not
part of the multidrug resistance phenotype mediated by the
mdrl gene (Toffoli et al., 1991), although a number of in vitro
studies have implicated roles for genes such as c-fos (Funato
et al., 1992), c-jun (Rubin et al., 1992), c-Ha ras (Isonishi et
al., 1991) and c-myc (Mizutani et al., 1994). However, to date
there is a dearth of in vivo investigations attempting to
examine the relationship between cisplatin therapy and the
expression of specific cellular oncogenes (Sklar and
Prochownik, 1991; Osmak et al., 1993; Taverna et al., 1994).
Antisense oligodeoxyribonucleotides are being applied to
modulate the expression of specific genes (Stein and Cheng,
1993) with phosphorothioate analogues preferred over the
conventional phosphodiester analogues because of their
superior hybridisation affinities and resistance to degradation
by nucleases (Iversen, 1991). In vitro studies using antisense c-
myc analogues have confirmed the role of c-myc in cellular
proliferation (Paria et al., 1992), signal transduction pathways
(Biro et al., 1993) and differentiation (Yang and Yang, 1995).
We have examined quantitative expression of the rat c-myc
gene following cisplatin therapy using a solid tumour model
serially transplantable in syngeneic DA rats. We find that the
rat c-myc gene displays a sustained 2-fold elevation in
expression following single-dose cisplatin chemotherapy.
These findings parallel reports linking an elevation in c-myc
expression with the onset of chemoresistance to cisplatin in
clinically derived human tumour lines (Mizutani et al., 1994).
We have also examined the effect of phosphorothioate
antisense RNAs targeted against c-myc upon cultured
tumour cells and discovered that a significant reduction in
cell growth rate is achievable in vitro. We hypothesise that
antisense therapy directed at c-myc in combination with
cisplatin may achieve therapeutic efficacies in vivo that greatly
exceed those displayed by either agent in isolation.
Materials and methods
Probe cDNAs
A 1.8 kbp EcoRI-bound murine c-myc cDNA cloned into the
EcoRI site of pBluescript plasmid was provided by Dr
Suzanne Cory, WEHI, Melbourne, Australia. Murine fJ-actin
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cDNA (1.1 kbp PstI-bound fragment in pUC19) was donated
by Dr Ismail Kola (CEHD, Monash University, Melbourne,
Australia).
Animals
Syngeneic DA rats (10-16 weeks old) were housed 3-4 per
cage, sex segregated in temperature-controlled rooms with a
12 h light/dark cycle. Food (crude pellet) and water were
provided ad libitum through wire-roofed plastic cages.
Animals were randomised by weight and sex into control
and treatment groups (ten animals per group).
Tumour implantation, treatment and removal
A solid transplantable rat salivary adenocarcinoma obtained
from the Lions Cancer Institute, Royal Perth Hospital, was
used as the experimental tumour model. Tumour studies were
conducted on the lateral aspect of the hind limbs of DA rats.
A small incision was made through the skin and a 1 mm3
piece of healthy tumour was implanted subcutaneously.
Tumour growth was assessed daily using calibrated vernier
calipers and expressed as the product of the minimal and
maximal length of tumour axes. This method has been used
extensively by this and other groups (Napoli et al., 1992;
Burton et al., 1990). The chemotherapeutic drug, cisplatin,
was administered on day 10 of tumour growth to the
treatment group. This point coincides with commencement of
the proliferative period of tumour growth. An intravenous
administration of cisplatin, equivalent to a low dose used in
the clinical setting (1 mg kg-'), was delivered via the inferior
vena cava and was performed during a laparotomy under
general anaesthesia. In both control and treatment groups
tumours were dissected free from the hind limbs after 6, 12
and 17 days growth and processed for RNA analysis. These
sample points were selected from data on in vivo tumour
growth kinetics (Figure 1) as a pretreatment time point (day
6) and two post-treatment time points, one during the phase
of tumour growth retardation (day 12) and the other well
after resumption of tumour growth (day 17).
Cell Cultures
Primary cell cultures were established from the in vivo
passaged tumour by seeding cells into fresh RPMI-1640
medium containing 5% fetal calf serum (FCS) (Trace
Biosciences) incubated at 37°C in 5% carbon dioxide. Media
were supplemented with antimicrobial/antimycotic PSN
antibiotics (Gibco-BRL). Cells were harvested with trypsin-
versene, washed three times with Hanks' balanced salt
solution (Trace) before pelleting by centrifugation
(3000 r.p.m.; 10 min) and processing for RNA extraction.
Antisense trials
The established in vitro cell culture was treated on day 3 of
cell growth with 5 ,UM dosages (selected from preliminary
studies, data not shown) of a 15-residue phosphorothioate
antisense oligodeoxyribonucleotide (5'-CACGTTGAGGGG-
CAT-3'). The antisense transcript was directed at the
translation initiation codon and next four codons
(MPLNV) of exon 2 in the rat c-myc gene (Hayashi et al.,
1987) and delivered upon the fifth passage of cell culture. In
addition, a scrambled sequence (mismatch) oligomer (5'-
AGCGTAGGCTAGCGT-3') was employed to confirm gene
specific inhibition of tumour cell growth. Cell numbers and
cell viability were monitored daily in triplicate.
Total RNA isolation
Total RNA was extracted from fresh tumour tissue samples
and harvested from cell cultures using TRIzol reagent
(Gibco-BRL). For tissues, a sample of healthy tumour
tissue (0.2 g) from freshly dissected tumours was homo-
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Figure 1 Growth curves for treated and untreated tumours.
Each point represents the mean of ten tumours (±1 s.d.). A
pretreatment sample (day 6) and two post-treatment samples
(days 12 and 17) were analysed for relative expression in both
treatment and control groups.
25 homogeniser (HD Scientific). For cell cultures approxi-
mately 2.3-4.6 x 106 cell samples were pelleted (2000 r.p.m.,
5 min), and lysed in TRIzol reagent for total RNA
preparation. Both homogenised and lysed samples were then
incubated at room temperature for 5 min. Chloroform was
added, the solution gently shaken and incubated at room
temperature for a further 2-3 min. After centrifugation
(12 000 g, 10 min at 40C), the RNA was precipitated from
the upper aqueous phase with the addition of isopropanol
(0.5 ml 1 ml-' TRIzol used), and incubated at room
temperature for 10 min. The RNA was pelleted (12 000 g,
10 min at 4°C) and washed in 1 ml of DEPC (diethyl
pyrocarbonate, BPH Chemicals) treated 70% ethanol,
repelleted (12 000 g, 5 min at 4°C) and dissolved in TE
buffer before gel fractionation.
RNA fractionation
Briefly, a 1.4% agarose (Promega) gel was cast using DEPC-
treated sterile water, 1 x MOPS [3-(N-Morpholinol) propane-
sulphonic acid] buffer (20 mM MOPS, 5 mM sodium acetate,
pH 7.0, 1.0 mM EDTA) and 6.3% formaldehyde (Sigma) in a
fume hood. RNA samples were prepared by combining 20 ,ug
total RNA in 2% deionised formamide, 1 x MOPS buffer,
16% formaldehyde buffer and denatured for 5 min at 65°C
before chilling on ice. Before loading on the gel, loading buffer
(50% v/v glycerol, 0.1 mg ml-' bromophenol blue) and 0.5 ,ug
ethidium bromide was added to each sample. The gel was run
at 0.5 V cm-' for 4 h in 1 x MOPS running buffer.
Fractionated RNA was transferred to Hybond-N membrane
(Amersham) using established techniques (Sambrook et al.,
1989). Fixation ofNorthern blots was carried out by exposing
the membrane to ultraviolet light for 2-3 min.
Hybridisation
cDNA inserts were cleaved free of vector plasmids and
purified with Bresaclean (Bresatec Ltd) before radiolabelling
with a -32P-dATP radioisotope by random priming with
Klenow DNA Polymerase using a GIGAprime kit
(Bresatec). Northern blots were hybridised with radiolabelled
probes in glass bottles containing hybridisation buffer
(10 mM Hepes, pH 7.0, 0.4 M sodium chloride, 0.04 M
trisodium citrate, 0.2% bovine serum albumin, 0.2% Ficoll,
0.2% polyvinylpyrrolidone, 2 ug ml- herring sperm, 0.1%
sodium dodecyl sulphate), which were rotated in a DNA HI-
2001 hybridisation incubator (Bartelt Instruments) for 16 h at
65°C. All blots were washed under high-stringency conditions
(0.015 M sodium chloride, 0.003 M trisodium citrate at 65°C)
and dried before exposure to Kodak XRP film. Autoradio-
graphs were scanned using a Hewlett Packard 8000 flatbed
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scanner and digitised as 256 greyscale graphic files. Blot
intensities were quantified using the Blotscan computer
program developed by RJ White, CSIRO, Griffith.
Statistical analysis
The mean and standard deviation of daily tumour sizes was
calculated for each animal group and plotted against time.
Raw data from each group was transformed (1) and
compared using linear regression analysis (Snedecor and
Cochran, 1967). Appropriate differences between means were
statistically examined using a t-test (Howell, 1982).
Results
In vivo tumour growth kinetics
The effect of cisplatin was examined by comparing the
tumour growth kinetics for untreated and treated animals
(Figure 1). The experiment was conducted five times,
accounting for the ten tumours measured. Regression line
analysis revealed that the untreated tumours had a
doubling rate of 3.65 days, while the treated tumours had
a doubling rate of 4 days. Cisplatin was administered on
day 10, a period that corresponded with the early onset of
the proliferative period of growth. Retardation of tumour
growth was evident in the treated animals for a period of
up to 48 h. Tumour growth resumed rates identical to
those of untreated animals following this 48 h period.
Statistical analysis of transformed (1) data demonstrates a
significant difference (P<0.05) between treated and
untreated groups showing that a single dosage of
intravenous cisplatin produces a significant retardation in
tumour growth rate.
In vitro tumour growth kinetics
The tumour cell growth kinetics for control, myc antisense
oligomer-treated and mismatch oligomer-treated samples are
shown in Figure 2. This experiment was repeated in triplicate.
Statistical analysis revealed no significant difference (P>0.05)
between control and mismatch treatment regression lines.
However, the c-myc antisense treatment group clearly
demonstrated significant difference in growth retardation of
cell populations (P<0.05) between control and mismatch
groups. Indeed, 25% growth retardation of tumour cells was
observed for a period of up to 4 days following the single
5 gLM dose of naked c-myc phosphorothioate antisense
oligomers. Maximal inhibition (42%) was observed 4 days
after administration.
c-myc expression
Autoradiograph blot intensities from each experimental
group for c-myc and /3-actin were determined using the
'Blotscan' program. Following digitisation, the values were
standardised with respect to values for f,-actin, and mean blot
intensity from each group in the in vivo study is shown in
Figure 3. The results demonstrate that 2 days (48 h) after
cisplatin treatment, a significant 2-fold rise (100%) in c-myc
expression was observed between control and treatment
groups (P=0.01). This elevation in expression was also
evident at the 7 day sample point (P=0.01). Expression of
the c-myc gene in tumour samples before treatment showed
no significant difference with the 2 day (P=0.81) or 7 day
(P=0.06) control sample points.
Relative expression of the c-myc gene from in vitro cell
cultures for control, myc antisense oligomer-treated and
mismatch oligomer-treated groups are shown in Figure 4.
There were no significant differences in the level of c-myc
expression between untreated and mismatch treatment groups
(P>0.05). c-myc transcripts were undetectable (at the
sensitivities afforded by this system), following c-myc
phosphorothioate antisense treatment suggesting virtually
complete inhibition of c-myc expression.
Discussion
Our in vivo studies demonstrate that a single low-dose
cisplatin treatment results in both tumour growth retarda-
tion and a 2-fold elevation in the level of c-myc expression.
Comparison of the 7 day sample points for untreated and
treated tumours suggests that the rise in expression may be a
constitutive feature of the surviving cells and not a transient
rise as the cells begin to recover from cytotoxic insult. This
reproducible 2-fold elevation in the expression of c-myc is
mirrored by reports of analysis conducted on both in vitro
cultured tumour cell lines (Marazzi et al., 1991) as well as
freshly isolated colon carcinoma tissues from patients with
failed cisplatin therapy (Kashani-Sabet et al., 1990).
The effect ofspecific induction of myc gene expression may
be explained by the presence of non-saturating dosages of
cisplatin reaching cells and random mutagenic action of the
drug upon the c-myc regulatory region. Cells whose myc
expression becomes elevated in this fashion may attain a
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Figure 2 Cell culture growth curves for c-myc antisense
oligonucleotide-treated, mismatch oligomer-treated and control
tumour groups. Fifth passage cell cultures were treated with 5,M
c-myc antisense on day 3 of cell growth. Each data point
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Figure 3 Relative expression of the c-myc gene as determined by
Northern blot hybridisation analysis of RNA isolated from the in
vivo serial transplantable tumour. Cisplatin was administered on
day 10 of tumour growth. Mean blot intensities (following
standardisation with values for ,B-actin expression) are shown for
each group (±1 s.d.); E, Pretreatment, day 6 (n =6); MC, control
group, day 12 (n =8); MT, treatment group, day 12 (n =4); LC,
control group, day 17 (n =7); LT, treatment group, day 17
(n = 10). RNA degradation accounts for variations in sample
numbers.
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Figure 4 Relative expression of the c-myc gene as determined
from Northern blot hybridisation analysis of in vitro tumour cell
cultures. Untreated (n =3), mismatch (n =3), antisense (n = 3).
Cells were treated with phosphorothioate oligomers on day 3 of
growth and harvested on day 6. Mean cell numbers used for
RNA harvest range from 2.3-4.5 x 106 cells in all cases. Mean
blot intensities, standardised using fi-actin as a control, are shown
for each treatment group (±1 s.d.).
chemotherapy treatment. The effect of this elevated expres-
sion upon tumour response to subsequent cisplatin insult
warrants further investigation.
Our in vitro studies have demonstrated that upon
suppression of c-myc expression using phosphorothioate
oligodeoxyribonucleotides, tumour cell growth is suspended
significantly for a period of up to 4 days. This time period of
growth inhibition coincides with the average half-life (4-5
days) of phosphorothioate oligodeoxynucleotides in serum
culture (Shaw et al., 1991). The most likely scenario is that
the cells are held in stasis in the Go or GI phases of the cell
cycle by suppression of c-myc expression as demonstrated in
other systems (Heikkila et al., 1987). In addition, Myc
protein is now known to modulate expression of the cyclin E
gene whose product mediates the Go to S-phase transition of
the cell cycle (Shichiri et al., 1993; Hanson et al., 1994). The
c-myc gene product appears to act as a transactivator,
controlling genes that mediate the transition from G, to S-
phase (Hanson et al., 1994). Treatment with c-myc antisense
oligomer may result in cells being held in the G, phase of the
cell cycle, which has been shown to be cisplatin sensitive
(Fraval and Roberts, 1978). Indeed, recent evidence from cell
culture studies favours this hypothesis. Mizutani et al. (1994)
reported a synergistic cytotoxic effect for c-myc antisense in
combination with cisplatin therapy for the T24 bladder
tumour line and two freshly derived urinary bladder cells in
culture. Interestingly, chemoresistance in these cells was
completely reversed by c-myc antisense treatment.
The molecular basis for chemoresistance to platinum-
based drugs is poorly understood. The rapid onset of
cisplatin chemoresistance is well documented in vitro and
parallels clinical observations (Andrews et al., 1990; Howell
et al., 1992). Although the basis for this resistance has been
variously ascribed to several candidate genes (Funato et al.,
1992; Rubin et al., 1992; Isonishi et al., 1991; Nakata et al.,
1994), no one gene has been consistently implicated, with the
exception of the c-myc gene (Kashani-Sabet et al., 1990;
Marazzi et al., 1991; Sklar and Prochownik, 1991; Niimi et
al., 1991; Mituzani et al., 1994). The presence of a cisplatin-
responsive element within the human c-myc gene promoter
was demonstrated by Spandidos et al. (1991), who defined it
within the region 290 and 350 bp upstream of the c-myc P1
cap site. Using transfected plasmids carrying the 5' c-myc
linked to the chloramphenicol acetyltransferase (CAT)
reporter gene, the authors were able to demonstrate that
cisplatin stimulated a 9- to 11-fold elevation in activity of the
CAT gene. Although our data demonstrate that relatively low
doses of cisplatin can evoke a significant rise in c-myc
expression, it is premature to suggest there is a direct link
between cisplatin use and c-myc-modulated chemoresistance.
Clearly, the mechanism for cisplatin chemoresistance remains
to be investigated.
Targeted genetic disruption of c-myc gene expression
represents an attractive new cancer treatment modality that
in combination with classical anti-cancer therapies offers the
potential for greatly enhanced therapeutic efficacies for
certain cancers. In addition, chemoresistance may be
reversed by gene-targeted antisense therapy directed at the
c-myc gene. The use of antisense technology may have clear
benefits particularly when used in conjunction with conven-
tional chemotherapies. We are presently attempting to
characterise c-myc expression in relation to the development
of cisplatin chemoresistance in vivo as a foundation for
evaluation of combination therapies in this tumour model.
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